ATE494902T1 - Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums - Google Patents

Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums

Info

Publication number: ATE494902T1
Authority: AT; Austria
Prior art keywords: gnrh; analogs; mammalian; tumor; tumor cell
Prior art date: 2000-03-31

Application number

AT00966971T

Other languages

English (en)

Inventor

Theresa M Siler-Khodr

Gabriel S Khodr

Original Assignee

Theresa M Siler-Khodr

Gabriel S Khodr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2000-09-26

Publication date

2011-01-15

2000-09-26 Application filed by Theresa M Siler-Khodr, Gabriel S Khodr filed Critical Theresa M Siler-Khodr

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE494902T1 publication Critical patent/ATE494902T1/de

Links

101000996738 Gallus gallus Gonadoliberin-2 Proteins 0.000 title 1
230000004565 tumor cell growth Effects 0.000 title 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 4
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 2
102000008238 LHRH Receptors Human genes 0.000 abstract 2
108010021290 LHRH Receptors Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 2
150000001413 amino acids Chemical group 0.000 abstract 2
239000000825 pharmaceutical preparation Substances 0.000 abstract 2
210000004881 tumor cell Anatomy 0.000 abstract 2
NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 abstract 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 abstract 1
241000252203 Clupea harengus Species 0.000 abstract 1
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 abstract 1
229930182819 D-leucine Natural products 0.000 abstract 1
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 1
102000005593 Endopeptidases Human genes 0.000 abstract 1
108010059378 Endopeptidases Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
108700015863 His(5)-Trp(7)-Tyr(8)- LHRH Proteins 0.000 abstract 1
102000035195 Peptidases Human genes 0.000 abstract 1
108091005804 Peptidases Proteins 0.000 abstract 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
150000001408 amides Chemical group 0.000 abstract 1
230000002001 anti-metastasis Effects 0.000 abstract 1
230000001028 anti-proliverative effect Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
230000001640 apoptogenic effect Effects 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
229940066758 endopeptidases Drugs 0.000 abstract 1
229940088598 enzyme Drugs 0.000 abstract 1
235000019514 herring Nutrition 0.000 abstract 1
235000019833 protease Nutrition 0.000 abstract 1
230000000541 pulsatile effect Effects 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Electrotherapy Devices (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT00966971T 2000-03-31 2000-09-26 Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums ATE494902T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/540,685 US7834141B1 (en)	2000-03-31	2000-03-31	Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
PCT/US2000/026575 WO2001074377A1 (en)	2000-03-31	2000-09-26	Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy

Publications (1)

Publication Number	Publication Date
ATE494902T1 true ATE494902T1 (de)	2011-01-15

Family

ID=24156514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00966971T ATE494902T1 (de)	2000-03-31	2000-09-26	Ein huhn gnrh-ii analog zur verwendung in der reduktion des tumorzellwachstums

Country Status (7)

Country	Link
US (2)	US7834141B1 (de)
EP (1)	EP1272206B1 (de)
JP (1)	JP2004512011A (de)
AT (1)	ATE494902T1 (de)
AU (1)	AU2000277238A1 (de)
DE (1)	DE60045524D1 (de)
WO (1)	WO2001074377A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6635739B2 (en) *	1999-10-15	2003-10-21	Theresa Siler-Khodr	Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
US20040152639A1 (en) *	2001-08-28	2004-08-05	Siler-Khodr Theresa M.	Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
US7361633B2 (en)	2002-07-22	2008-04-22	Ardana Bioscience Limited	Screening method and anti-tumor drug candidate obtained therefrom
EP1539959A2 (de) *	2002-09-18	2005-06-15	Centre Hospitalier de l'Université de Montréal (CHUM)	Ghrh-analoge
WO2004063221A1 (ja)	2002-12-26	2004-07-29	Takeda Pharmaceutical Company Limited	メタスチン誘導体およびその用途
US7754220B2 (en)	2003-03-12	2010-07-13	Takeda Pharmaceutical Company Limited	Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
US20050043245A1 (en) *	2003-08-11	2005-02-24	Siler -Khodr Theresa M.	Non-mammalian GnRH analogs and uses thereof in the immune system
EP1605962A1 (de) *	2003-08-12	2005-12-21	Theresa M. Siler-Khodr	Gnrh-analoga von nicht-säugern und deren verwendung bei der regulation von fruchtbarkeit und schwangerschaft
US20050054576A1 (en) *	2003-08-12	2005-03-10	Siler-Khodr Theresa M.	Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
WO2006001499A2 (en)	2004-06-25	2006-01-05	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US8334258B2 (en)	2005-07-26	2012-12-18	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin)	Method for induction and enhancement of apoptosis in tumor cells
AR058584A1 (es)	2005-12-22	2008-02-13	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos
US8404643B2 (en)	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
GB0616111D0 (en)	2006-06-16	2006-09-20	Ardana Bioscience Ltd	Agents, methods and uses
JO3048B1 (ar)	2006-10-25	2016-09-05	Takeda Pharmaceuticals Co	مشتقات متاستين واستخدامها
PT2350316E (pt) *	2008-10-20	2014-06-23	Valipharma	Métodos e utilizações envolvendo aberrações genéticas de nav3 e expressão aberrante de genes múltiplos
US20120045393A1 (en) *	2009-03-17	2012-02-23	Linder Karen E	Lhrh-ii peptide analogs
US9241899B2 (en)	2013-03-13	2016-01-26	Transdermal Biotechnology, Inc.	Topical systems and methods for treating sexual dysfunction
US9320706B2 (en)	2013-03-13	2016-04-26	Transdermal Biotechnology, Inc.	Immune modulation using peptides and other compositions
US9314417B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Treatment of skin, including aging skin, to improve appearance
US9724419B2 (en)	2013-03-13	2017-08-08	Transdermal Biotechnology, Inc.	Peptide systems and methods for metabolic conditions
US9387159B2 (en)	2013-03-13	2016-07-12	Transdermal Biotechnology, Inc.	Treatment of skin, including aging skin, to improve appearance
US9314433B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Methods and systems for treating or preventing cancer
US9393265B2 (en)	2013-03-13	2016-07-19	Transdermal Biotechnology, Inc.	Wound healing using topical systems and methods
US9295636B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Wound healing using topical systems and methods
US9314422B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Peptide systems and methods for metabolic conditions
US9314423B2 (en)	2013-03-13	2016-04-19	Transdermal Biotechnology, Inc.	Hair treatment systems and methods using peptides and other compositions
US9687520B2 (en)	2013-03-13	2017-06-27	Transdermal Biotechnology, Inc.	Memory or learning improvement using peptide and other compositions
US20140271731A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Cardiovascular disease treatment and prevention
US9393264B2 (en)	2013-03-13	2016-07-19	Transdermal Biotechnology, Inc.	Immune modulation using peptides and other compositions
US9295647B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Systems and methods for delivery of peptides
US20140271938A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Systems and methods for delivery of peptides
US20140271937A1 (en)	2013-03-13	2014-09-18	Transdermal Biotechnology, Inc.	Brain and neural treatments comprising peptides and other compositions
US9295637B2 (en)	2013-03-13	2016-03-29	Transdermal Biotechnology, Inc.	Compositions and methods for affecting mood states
US9750787B2 (en)	2013-03-13	2017-09-05	Transdermal Biotechnology, Inc.	Memory or learning improvement using peptide and other compositions
US9849160B2 (en) *	2013-03-13	2017-12-26	Transdermal Biotechnology, Inc.	Methods and systems for treating or preventing cancer
US9320758B2 (en)	2013-03-13	2016-04-26	Transdermal Biotechnology, Inc.	Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en)	2013-03-13	2016-05-17	Transdermal Biotechnology, Inc.	Cardiovascular disease treatment and prevention
JP2020505379A (ja) *	2017-01-20	2020-02-20	イミューンシステムレギュレェイションホールディングエービー	新規化合物（イムノレリン）
JP2020505378A (ja) *	2017-01-20	2020-02-20	イミューンシステムレギュレェイションホールディングエービー	新規化合物（イムノヘリン−細胞内感染）
JP7541822B2 (ja)	2017-01-20	2024-08-29	アイエスアールイミューンシステムレギュレイションホールディングアクチエボラグ（パブル）	既知の化合物の新規使用－細胞内感染
CN110381978A (zh)	2017-02-22	2019-10-25	免疫系统调节控股有限公司	促性腺激素释放激素用作辅助免疫治疗剂的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2029018A1 (en) *	1989-11-01	1991-05-02	Robert P. Millar	Analogues of gonadotropin releasing hormone
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US6635739B2 (en) *	1999-10-15	2003-10-21	Theresa Siler-Khodr	Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
US6323179B1 (en) *	1999-10-15	2001-11-27	Theresa Siler-Khodr	Chicken GNRH analogs and uses thereof in regulation of fertility and pregnancy

2000
- 2000-03-31 US US09/540,685 patent/US7834141B1/en not_active Expired - Fee Related
- 2000-09-26 AU AU2000277238A patent/AU2000277238A1/en not_active Abandoned
- 2000-09-26 EP EP00966971A patent/EP1272206B1/de not_active Expired - Lifetime
- 2000-09-26 AT AT00966971T patent/ATE494902T1/de not_active IP Right Cessation
- 2000-09-26 WO PCT/US2000/026575 patent/WO2001074377A1/en not_active Ceased
- 2000-09-26 JP JP2001572119A patent/JP2004512011A/ja active Pending
- 2000-09-26 DE DE60045524T patent/DE60045524D1/de not_active Expired - Lifetime
2003
- 2003-09-03 US US10/654,192 patent/US20040097412A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040097412A1 (en)	2004-05-20
EP1272206B1 (de)	2011-01-12
JP2004512011A (ja)	2004-04-22
EP1272206A1 (de)	2003-01-08
US7834141B1 (en)	2010-11-16
DE60045524D1 (de)	2011-02-24
AU2000277238A1 (en)	2001-10-15
WO2001074377A1 (en)	2001-10-11

Legal Events

Date	Code	Title	Description
2011-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60045524D1 (de)	2011-02-24	Ein Huhn GnRH-II Analog zur Verwendung in der Reduktion des Tumorzellwachstums
EP1626055A3 (de)	2006-03-08	Nicht von Säugetieren stammende GnRH Analoga und deren Verwendung zur Regulierung des Immunsystems
NZ592510A (en)	2012-11-30	HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
ATE204881T1 (de)	2001-09-15	Chimäre lipidkörper-pro-grf analoge mit erhöheter biologischer potenz
ATE245659T1 (de)	2003-08-15	Insulinabkömmlinge
PL370823A1 (en)	2005-05-30	Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
DE69434181D1 (de)	2005-01-13	Therapeutische Peptid Derivate
ATE172742T1 (de)	1998-11-15	Peptide mit wachstumshormonfreisetzender aktivität
ES2159184T3 (es)	2001-09-16	Nueva posologia para la dmni.
MY103746A (en)	1993-09-30	Improvements in or relating to somatostatins
ATE311453T1 (de)	2005-12-15	Grf-analoge mit erhöhter biologischer potenz
DE60138552D1 (de)	2009-06-10	Peptide mit integrinbindungsmotiv und behandlungsmethoden für muskelkrankheiten
MX9703642A (es)	1998-11-29	Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
ATE206914T1 (de)	2001-11-15	Verwendung von ursolsäure zur herstellung eines arzneimittels zur unterdrückung von metastasen
AU6410201A (en)	2002-01-14	Peptide composition
YU53803A (sh)	2006-03-03	Peptidi i/ili proteini kao i njihova primena za pripremanje terapeutskih i/ili preventivnih lekova
ATE546461T1 (de)	2012-03-15	Gnrh analog von nicht-säugertieren und verwendung zur regulierung der fruchtbarkeit und der schwangerschaft
MY136546A (en)	2008-10-31	A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
WO2005018657A3 (en)	2005-04-07	NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
DE60237784D1 (de)	2010-11-04	Verfahren zur verabreichung eines thymosin-alpha 1 peptids
DE69430416D1 (de)	2002-05-23	Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
NO894720L (no)	1990-01-29	Farmasoeytisk aktivt protein.
EP1586581A3 (de)	2005-12-21	Nicht von Säugetieren stammende GnRH Analoga und deren Verwendungen zur Regulierung von Fertilität und Schwangerschaft
DE69834929D1 (de)	2006-07-27	Verwendung eines organspezifischen ernährungmittels
IT1283134B1 (it)	1998-04-07	Derivati sintetici e semisintetici di somatostatine utili nella stimolazione della crescita corporea, in particolare in